Collegium Pharmaceutical has avoided a significant regulatory setback with a late-stage FDA pushing back a review for NexaFilm (aluminum hydroxide coating). Investors have shown little immediate reaction to the delay, as management continues to present the data as supportive of a filing later this year and the company advances toward commercial launch with aidanmecilumab treatment.